• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Dec. 21, 2016

View Archived Issues

Appointments and advancements

Intellia Therapeutics Inc., of Cambridge, Mass., appointed Graeme Bell chief financial officer. Read More

In the clinic

Gensight Biologics SA, of Paris, reported additional data after 78 weeks of follow-up in its phase I/II trial, confirming the safety and tolerability profile of GS010, while demonstrating sustainable visual acuity improvement in patients with Leber's hereditary optic neuropathy (LHON). Read More

Other news to note

Pvp Biologics Inc., of Seattle, a University of Washington (UW) spinout, said it is advancing an enzyme, Kumamax, designed to target parts of gluten that cause the autoimmune reaction leading to celiac disease. Read More

Financings

Celsion Corp., of Lawrenceville, N.J., said it entered a definitive agreement with several institutional investors to purchase an aggregate of about $1.8 million of shares of common stock in a registered direct offering. Read More

China's Yifan acquires R&D biologics firm Generon for $180M

SHANGHAI – Shanghai-based Generon Corp. Ltd. was acquired by the world's leading manufacturer of vitamin B5 API, Yifan Pharmaceutical Co. Ltd., a public company listed in Shenzhen. Yifan has a portfolio of drugs approved in China for gynecology, pediatrics and dermatology, a portion of which are traditional Chinese medicine (TCM) products. Read More

Allergan to pay $2.9B for Lifecell, partly driven by breast cancers

Allergan plc said it will buy Lifecell Corp., a company that makes regenerative medicine products for tissue reinforcement, from privately held Acelity LP for $2.9 billion in cash, a purchase partly driven by growing demand for reconstructive breast surgeries among women with breast cancer. Read More

Psioxus inks $936M preclinical oncolytic virus deal with BMS

LONDON – Psioxus Therapeutics Ltd. has signed a potential $936 million deal with Bristol-Myers Squibb Co. (BMS) for NG-348, an armed oncolytic virus that delivers the genes for two T-cell mobilizing proteins. Read More

Caspase embraced: Novartis, Conatus $700M deal proves once-doubted class is no FXR-upper

Novartis AG's farnesoid X receptor (FXR) agonists represent "an excellent first opportunity for combination products" in liver disease, Conatus Pharmaceuticals Inc. CEO Steven Mento told BioWorld Today, but not necessarily the only prospect for pairing with oral pan-caspase inhibitor emricasan. "There could be others." Read More

Otsuka 'checks all the boxes' for Akebia in potential $1B+ vadadustat deal

While most analysts and investors were focused on its discussions with potential European partners, Akebia Therapeutics Inc. turned to Asia, again, for a U.S. development and commercialization collaborator for its lead candidate, vadadustat. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 18, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 18, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 15, 2025
  • Brain and neural networks

    Proteomics finds surprise commonalities as well as differences in neurodegenerative diseases

    BioWorld
    The switch will be flicked today to make the world’s largest dementia-related proteomics dataset freely available to researchers, at the same time as members of...
  • 3D rendering of a molecular glue mediating the interaction between two proteins

    With surface mimicry, molecular glues shed hairpin need

    BioWorld Science
    Degradation is a therapeutic strategy that could offer possibilities to get at currently undruggable target proteins. In targeted degradation, compounds induce...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe